All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to the Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR. We asked, When can we safely discontinue interferon alpha therapy in patients with myeloproliferative neoplasms?
When can we safely discontinue interferon alpha therapy in patients with MPN?
Kiladjian reports the results of a study comparing the clinical outcome of patients with myeloproliferative neoplasms who discontinued therapy after at least three months of interferon alpha treatment to patients who continued interferon alpha treatment despite achieving a complete hematological remission.
Interferon therapy in the management of myeloproliferative neoplasms
Treatment with interferon (IFN) therapy is considered successful for patients with myeloproliferative neoplasms (MPN), such as polycythemia vera (PV) and essential thrombocythemia...
Educational theme | The role of interferon-alpha in the treatment of MPN
Interferons (IFN) are cytokines released by host cells to induce innate immune response against viral infections and are characterized by immunomodulatory, antiproliferative,...
Subscribe to get the best content related to MPN delivered to your inbox